These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28747103)

  • 41. Treatment switching in oncology trials and the acceptability of adjustment methods.
    Latimer NR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):561-4. PubMed ID: 25893990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Value-Based Calculators in Cancer: Current State and Challenges.
    Nabhan C; Feinberg BA
    J Oncol Pract; 2017 Aug; 13(8):499-506. PubMed ID: 28617618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
    Driedger SM; Cooper E; Annable G; Brouwers M
    Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
    de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
    Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New treatments for advanced cancer: an approach to prioritization.
    Ferguson JS; Summerhayes M; Masters S; Schey S; Smith IE
    Br J Cancer; 2000 Nov; 83(10):1268-73. PubMed ID: 11044348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advancing the WHO-INTEGRATE Framework as a Tool for Evidence-Informed, Deliberative Decision-Making Processes: Exploring the Views of Developers and Users of WHO Guidelines.
    Stratil JM; Paudel D; Setty KE; Menezes de Rezende CE; Monroe AA; Osuret J; Scheel IB; Wildner M; Rehfuess EA
    Int J Health Policy Manag; 2022 May; 11(5):629-641. PubMed ID: 33131223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Methodology of economic assessment: example in oncology].
    Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
    Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ethical Hurdles in the Prioritization of Oncology Care.
    de Groot F; Capri S; Castanier JC; Cunningham D; Flamion B; Flume M; Herholz H; Levin LÅ; Solà-Morales O; Rupprecht CJ; Shalet N; Walker A; Wong O
    Appl Health Econ Health Policy; 2017 Apr; 15(2):119-126. PubMed ID: 27766548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cost-effectiveness of cancer drug treatments].
    Akazawa M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():706-12. PubMed ID: 25831852
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug repurposing in oncology--patient and health systems opportunities.
    Bertolini F; Sukhatme VP; Bouche G
    Nat Rev Clin Oncol; 2015 Dec; 12(12):732-42. PubMed ID: 26483297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
    Jenei K; Peacock S; Burgess M; Mitton C
    Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Approaches to Capturing Value in Oncology.
    Walter E
    Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 59. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What factors hinder the decision-making process for women with cancer and contemplating fertility preservation treatment?
    Jones G; Hughes J; Mahmoodi N; Smith E; Skull J; Ledger W
    Hum Reprod Update; 2017 Jul; 23(4):433-457. PubMed ID: 28510760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.